\
&
Contact us
\
&
Contact us
Pick a topic from the menu to get started.
With the blind evaluation pilot, the Commission wants to tackle concerns of any real or perceived effect of reputational bias that could subvert the awarding decision. Blind evaluation therefore requires that evaluators do not know the consortium and the applicants involved. As a consequence, applicants need to make the necessary adjustments when writing their proposals. To bring clarity about what is expected of applicants, NCP Flanders organised a webinar which took place on 15 June 2023.
Pick a topic from the menu to get started.
The METHYLOMIC project, ‘targeting hope for personalised medicine in immune-mediated inflammatory diseases’ obtained funding from Horizon Europe’s Health Cluster. The project aims to personalise treatment allocation and enhance the effectiveness of medications for chronic immune-mediated diseases such as Crohn’s disease, rheumatoid arthritis, and psoriasis. BIRD, the Belgian inflammatory bowel disease research and development group, is a partner in the project and is involved in the OmiCrohn trial, a prospective randomised clinical trial for individualised therapy in Crohn’s disease patients. With BIRD’s active role in this trial, the project is set to deliver predictive, biomarker-based therapies that bring renewed hope for Crohn’s disease patients across Europe.
